China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase

2nd December 2019 Uncategorised 0

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage in the world’s second largest pharmaceutical market. AbbVie, AstraZeneca and Bayer are among multinational companies to have reached deals with the Chinese government to include steeply discounted drugs in the country’s insurance scheme.

More: China gives Merck, BMS cold shoulder on reimbursement list as PD-1 battle enters new phase
Source: fierce